Invivyd, Inc. (IVVD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Invivyd, Inc. is a biopharmaceutical company focused on monoclonal antibodies for viral infectious diseases. Its primary commercial product is PEMGARDA® (pemivibart), which received Emergency Use Authorization (EUA) in March 2024 for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals. The company is advancing its next-generation candidate, VYD2311, with Phase 3 trials (DECLARATION and LIBERTY) expected to begin by year-end 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $13.1 million | $9.3 million | $36.2 million | $11.6 million |
| Net Loss | $(10.5) million | $(60.7) million | $(41.4) million | $(151.5) million |
| Net Loss Per Share | $(0.06) | $(0.51) | $(0.30) | $(1.28) |
| Operating Cash Flow | — | — | $(42.7) million | $(132.9) million |
| Cash & Equivalents (End of Period) | $85.0 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $943.4 million (as of Sept 30, 2025) |
Note: Gross margin for Q3 2025 was approximately 91.7% ($12.0M gross profit / $13.1M revenue). Management notes that reported margins would approach 80% if pre-EUA manufacturing costs had been capitalized.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 41% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 213% year-to-date, driven by increased sales of PEMGARDA following its launch.
- Expense Reduction: Total operating expenses decreased significantly. Research and Development (R&D) expenses dropped from $57.9 million in Q3 2024 to $8.0 million in Q3 2025. This $49.8 million decrease was primarily due to reduced contract costs for commercial manufacturing and clinical trials for VYD2311 and pemivibart.
- Loss Narrowing: Net loss improved substantially from $60.7 million in Q3 2024 to $10.5 million in Q3 2025, reflecting both revenue growth and significant cost containment.
- Capital Raise: In August 2025, the company completed an underwritten public offering, raising approximately $53.5 million in net proceeds through the sale of common stock and pre-funded warrants.
Outlook, Risks, and Contingencies
- Going Concern Warning: The company has concluded there is substantial doubt about its ability to continue as a going concern. Based on current plans and excluding future financing or revenue, cash reserves are insufficient to fund operations beyond one year from the filing date.
- Future Funding Needs: Invivyd requires additional funding via equity offerings, debt, or collaborations to support the REVOLUTION clinical program for VYD2311 and ongoing commercialization of PEMGARDA.
- Debt Facility: A $30 million senior secured term loan facility with Silicon Valley Bank was established in April 2025. However, as of September 30, 2025, the company had not satisfied the net product revenue milestones required to draw down funds.
- Regulatory Pathway: The FDA has advised that a single pivotal trial could support a Biologics License Application (BLA) for VYD2311. Top-line data for Phase 3 trials is anticipated in mid-2026.
- Nasdaq Compliance: The company previously received deficiency notices regarding the minimum bid price requirement but regained compliance in September 2025. Continued listing remains contingent on maintaining stock price levels.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $85.0 million cash balance against the projected burn rate for the upcoming Phase 3 trials and commercialization efforts.
- Debt Covenants: Review the specific net product revenue milestones required to access the $30 million loan facility and the likelihood of meeting them.
- PEMGARDA Sales Trajectory: Assess whether current revenue growth is sustainable given the EUA limitations and variant susceptibility thresholds.
- Capital Dilution: Monitor upcoming equity offerings (ATM facility and shelf registration) and their potential impact on shareholder dilution.
- Clinical Timeline: Confirm the start dates for the DECLARATION and LIBERTY Phase 3 trials and the projected mid-2026 data readout.